Although some clinical results with older drugs acting at 5-HT1A receptors were disappointing, all these data suggested that appropriate targeting of 5-HT1A receptors could improve a wide range of CNS disorders if suitable pharmacotherapeutics were available. This evidence concerns the gene HTR1A and central nervous system disorder.